BioMarin Pharmaceutical raised its full-year 2026 revenue guidance to between US$3.88 billion and US$3.93 billion and filed a US$719.24 million common stock shelf registration for an ESOP-related offering. The company reported second-quarter 2026 revenue of US$989.71 million and provided more detailed third and fourth quarter expectations, with the higher outlook leaning on a stronger fourth quarter and Amicus contribution. The raised guidance modestly reinforces the near-term growth catalyst but does little to reduce the key risk around rising costs outpacing revenue and the potential need for further dilutive financing if performance weakens. Some of the lowest analysts were already cautious, assuming about US$4.5 billion revenue and US$752.9 million earnings by 2029, focusing heavily on pricing and reimbursement risk.
Biomarin Pharmaceutical IncRaised 2026 revenue guidance and filed ESOP shelf, but cost concerns and potential dilution temper outlook.
